Development of a novel HEK293 cell model lacking SLC29A1 to study the pharmacology of endogenous SLC29A2-encoded equilibrative nucleoside transporter subtype 2

Nayiar Shahid; Christopher Cromwell; Basil P Hubbard; James R Hammond

doi:10.1124/dmd.124.001814

OtherArticle

**Development of a novel HEK293 cell model lacking SLC29A1 to study the pharmacology of endogenous SLC29A2-encoded equilibrative nucleoside transporter subtype 2**

Nayiar Shahid, Christopher Cromwell, Basil P Hubbard and James R Hammond

Drug Metabolism and Disposition July 25, 2024, DMD-AR-2024-001814; DOI: https://doi.org/10.1124/dmd.124.001814

Nayiar Shahid

1Pharmacology, University of Alberta, Canada

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Christopher Cromwell

1Pharmacology, University of Alberta, Canada

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Basil P Hubbard

1Pharmacology, University of Alberta, Canada

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

James R Hammond

1Pharmacology, University of Alberta, Canada

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for James R Hammond
For correspondence: james.hammond@ualberta.ca

Article
Info & Metrics
eLetters
PDF

Compose eLetter

Title *

Contents

More information about text formats

Plain text

No HTML tags allowed.
Web page addresses and e-mail addresses turn into links automatically.
Lines and paragraphs break automatically.

Author Information

Contributors
First Name and Middle Initial * First or given name, e.g. 'Peter'. Last Name * Your last, or family, name, e.g. 'MacMoody'. Email Address * Your email address, e.g. higgs-boson@gmail.com Occupation * Your role and/or occupation, e.g. 'Orthopedic Surgeon'. Affiliation * Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.

Statement of Competing Interests

Competing interests? *

Yes

Please describe the competing interests

Vertical Tabs

Jump to comment:

No eLetters have been published for this article.

PreviousNext

In this issue

Drug Metabolism and Disposition

Vol. 52, Issue 10

1 Oct 2024

Table of Contents
Table of Contents (PDF)
Index by author
Editorial Board (PDF)
Front Matter (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Development of a novel HEK293 cell model lacking SLC29A1 to study the pharmacology of endogenous SLC29A2-encoded equilibrative nucleoside transporter subtype 2

Message Subject (Your Name) has forwarded a page to you from Drug Metabolism & Disposition

Message Body (Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Citation Tools

OtherArticle

A novel cell model to examine the characteristics of ENT2

Nayiar Shahid, Christopher Cromwell, Basil P Hubbard and James R Hammond

Drug Metabolism and Disposition July 25, 2024, DMD-AR-2024-001814; DOI: https://doi.org/10.1124/dmd.124.001814

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

OtherArticle

A novel cell model to examine the characteristics of ENT2

Nayiar Shahid, Christopher Cromwell, Basil P Hubbard and James R Hammond

Drug Metabolism and Disposition July 25, 2024, DMD-AR-2024-001814; DOI: https://doi.org/10.1124/dmd.124.001814

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Jump to section

Article
Info & Metrics
eLetters
PDF

Main menu

User menu

Search

**Development of a novel HEK293 cell model lacking SLC29A1 to study the pharmacology of endogenous SLC29A2-encoded equilibrative nucleoside transporter subtype 2**

Plain text

Vertical Tabs

Jump to comment:

In this issue

A novel cell model to examine the characteristics of ENT2

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Navigate

More Information

ASPET's Other Journals